Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

PHASE3CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions
Paroxysmal Hemoglobinuria, Nocturnal
Interventions
DRUG

eculizumab

Trial Locations (40)

8

St. James's Hospital, Cancer Clinical Trial Office, Dublin

1200

Ucl St. Luc, Hematology Department, Brussels

2065

Royal North Shore Hospital, Haematology Department, Saint Leonards

3050

Royal Melbourne Hospital, Department of Clinical Haematology & Medical Oncology, Parkville

4102

Princess Alexandra Hospital, Oncology Haematology Radiation Department, Woolloongabba

5011

The Queen Elizabeth Hospital, Haematology/Oncology Department, Woodville South

6000

The Royal Perth Hospital, Department of Haematology/Level 2, Perth

6525

UMC St. Radboud, Department of Hematology, Nijmegen

10016

NYU Clinical Cancer Center, New York

10017

Memorial Sloan Kettering Cancer Center, New York

19104

Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thombosis Program, Philadelphia

20892

National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda

21205

Johns Hopkins University Medical Center, Baltimore

27710

Duke University Medical Center, Division Cell Therapy, Heme Malignancies Program, Durham

28046

Hospital De La Paz, Servicio de Hematologia, Madrid

33331

Cleveland Clinic Florida, Department of Clinical Research, Weston

44195

Cleveland Clinic Foundation, Cleveland

46202

Indianapolis University Cancer Center, Indianapolis

50139

Azienda Ospedaliera Universitaria Careggi, Dipartimento di area critica medico-chirurgica, Florence

55902

Mayo Clinic, Divison of Hematology, Rochester

63110

Washington University, Department of Internal Medicine/Division of Hematology, St Louis

94305

Stanford University Medical Center, Division of Hematology, Stanford

06102

Hartford Hospital, Cancer Clinical Research Office, Hartford

02114

Massachusetts General Hospital, Boston

T6G 2B7

University of Alberta, Cross Cancer Institute, Edmonton

N6A4L6

London Regional Cancer Centre, Clinical Research Unit Room C3080, London

10 75475

Hopital Saint Louis, Centre d'investigation Clinique, Paris

D-45147

Universitatsklinikum Essen, Zentrum fur Innere Medizin, Essen

D-30625

Medizinische Hochschule Hannover, Abt. Hamatologie/Onkologie, Zentrum fur Innere Medizin, Hanover

D-66421

Universitatskliniken des Saarlandes, Innere Medizin 1, Homburg/Saar

D-89081

Institut fur Klinische Transfusionmedizin und Immunogenetik, Abtlg. Transfusionmedizin des Univ. Ulm, Ulm

I-16132

Ospedale San Martino, Department of Hematology, Genova

35-20122

Ospedale Maggiore di Milano, Divisione di Ematologia, Milan

5-80131

Universita degli Studi di Napoli, Divisione di Ematologia, Azienda Universitar Policlinico, Napoli

37-36100

Ospedale San Bortolo, Divisione di Ematologia, Vicenza

08036

Hospital Clinic i Provincial, Servicio de Hematologia, Barcelona

08916

Hospital Universitario Germans Trias I Pujol, Servicio de Hematologia, Barcelona

118-83

Stockholm South Hospital, Division of Hematology, Stockholm

LS1 3EX

Leeds General Infirmary, D Floor Brotherton Wing, Leeds

SW17OQT

St. George's Hospital, Department of Haematology, London

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY

NCT00122317 - Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) | Biotech Hunter | Biotech Hunter